Independent reference. Not affiliated with, endorsed by, or speaking for the U.S. Food and Drug Administration.
FDA Medication Tracker

← All approvals · Weight loss & diabetes · 2026

Onswik (insulin efsitora alfa-gobe)

The FDA approved Onswik (insulin efsitora alfa-gobe) on September 23, 2026 to improve glycemic control in adults with type 2 diabetes mellitus, as an adjunct to diet and exercise.
Brand name
Onswik
Generic name
insulin efsitora alfa-gobe
FDA approval date
September 23, 2026
Approved use (FDA wording)
To improve glycemic control in adults with type 2 diabetes mellitus, as an adjunct to diet and exercise
Category on this site
Weight loss & diabetes

Official sources

Facts only. This site lists what the FDA has approved and what the FDA says each drug is approved for, quoted or closely paraphrased from FDA and openFDA records. It gives no medical advice, no dosing, and no comparisons, and it says nothing about whether a drug is right for anyone. Talk to a licensed clinician about any medication. Records can lag or contain errors; the FDA's own pages are authoritative.